Inomagen Therapeutics
PrivateLast Round
Seed
Aug 1, 2024
Total Funding Raised
$4.07M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Inomagen Therapeutics operates in Healthcare & Life Sciences and is based in Chicago, Illinois. Its latest recorded funding round was a Convertible Debt round in January 2023.
Inomagen Therapeutics is a biotechnology company developing a non-viral gene therapy designed to treat the underlying mechanisms of atrial fibrillation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inomagen Therapeutics Comparables
Compare Inomagen Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rhythm Biotherapeutics | 75% | |
| Renova Therapeutics | 70% | |
| Medera | 66% |
For institutional investors. Book with your work email.
Inomagen Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Aug 1, 2024 | ||||
| Convertible Debt | Jan 1, 2023 | ||||
| Grant | Mar 11, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Inomagen Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| National Heart, Lung, and Blood Institute | Grant |
| Portal Innovations | Convertible Debt |
| Chicago ArchAngels | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 185% MoM.
- Apr 20, 2026
Monthly visitors grew 938% MoM, from 128 to 1.3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 16, 2026
Inomagen Therapeutics, Inc. receives a $3.67M NIH SBIR grant in Illinois in 2021 to support its atrial fibrillation program.
- receives_financingSep 16, 2026
On Sep 16th '26 in Illinois, Inomagen Therapeutics, Inc. receives a $2.9M Small Business Innovation Research grant from the NHLBI of the National Institutes of Health to support preclinical and manufacturing activities for its investigational plasmid-based therapy.
- is_developingSep 16, 2026
Inomagen Therapeutics, Inc. is developing a novel gene therapy approach to provide more effective treatment for patients with atrial fibrillation, with NIH SBIR support for preclinical and manufacturing activities toward a future IND application in Illinois on Sep 16th '26.
- is_developingSep 16, 2026
On Sep 16th '26 in Illinois, Inomagen Therapeutics, Inc. develops therapeutic transgenes designed to target molecular mechanisms contributing to atrial fibrillation and a catheter-based electroporation platform for non-viral cardiac gene delivery.
For institutional investors. Book with your work email.
Inomagen Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Inomagen Therapeutics's valuation, stock price, and market status.
Is Inomagen Therapeutics a public or private company?
Inomagen Therapeutics is a private company.
What is the current stock price of Inomagen Therapeutics?
Inomagen Therapeutics is a private company, so its shares have no public market price. Caplight tracks Inomagen Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inomagen Therapeutics worth (valuation)?
Valuation information for Inomagen Therapeutics is not publicly available.
Can I buy Inomagen Therapeutics stock?
Inomagen Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inomagen Therapeutics's last funding round?
Inomagen Therapeutics's most recent funding round was Seed on August 1, 2024.
Who are the main investors in Inomagen Therapeutics?
Key investors in Inomagen Therapeutics include NIH RADx, National Heart, Lung, and Blood Institute, Portal Innovations, Chicago ArchAngels.
Will Inomagen Therapeutics IPO soon?
No public IPO plans have been announced for Inomagen Therapeutics.
How can I track Inomagen Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Inomagen Therapeutics's shares on secondary markets.